| Population 2015 |
46 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
0.26 |
(0.26–0.27) |
0.57 |
(0.57–0.58) |
| Mortality (HIV+TB only) |
0.054 |
(<0.01–0.27) |
0.12 |
(0–0.58) |
| Incidence (includes HIV+TB) |
5.5 |
(4.7–6.4) |
12 |
(10–14) |
| Incidence (HIV+TB only) |
0.4 |
(0.34–0.48) |
0.87 |
(0.73–1) |
| Incidence (MDR/RR-TB)** |
0.042 |
(0.016–0.069) |
0.09 |
(0.03–0.15) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0.18 |
(0.092–0.26) |
2 |
(1.5–2.6) |
2.2 |
(1.5–2.9) |
| Males |
0.21 |
(0.14–0.28) |
3.1 |
(2.4–3.8) |
3.3 |
(2.6–4.1) |
| Total |
0.39 |
(0.29–0.49) |
5.1 |
(4.7–5.6) |
5.5 |
(4.7–6.4) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
4 191 |
| Total new and relapse |
4 026 |
| - % tested with rapid diagnostics at time of diagnosis |
11% |
| - % with known HIV status |
|
| - % pulmonary |
74% |
| - % bacteriologically confirmed among pulmonary |
82% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
73% (63–85) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.06 (0.03–0.09) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
|
|
| - on antiretroviral therapy |
|
|
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
25
(10–40) |
| Estimated % of TB cases with MDR/RR-TB |
0.44% (0.12–1.1) |
7.1% (3.3–13) |
|
| % notified tested for rifampicin resistance |
|
|
|
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
|
| Laboratory-confirmed cases |
MDR/RR-TB: , XDR-TB: |
| Patients started on treatment **** |
MDR/RR-TB: , XDR-TB: |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
58% |
4 689 |
| Previously treated cases, excluding relapse, registered in 2014 |
52% |
228 |
| HIV-positive TB cases, all types, registered in 2014 |
39% |
200 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
|
|
| XDR-TB cases started on second-line treatment in 2013 |
|
|
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |